Cartesian Therapeutics, Inc. (RNAC)
7.00
+0.22
(+3.24%)
USD |
NASDAQ |
Nov 06, 10:23
Cartesian Therapeutics Enterprise Value : 119.90M for Nov. 5, 2026
Enterprise Value Chart
Historical Enterprise Value Data
| Date | Value |
|---|---|
| November 05, 2026 | 119.90M |
| November 04, 2026 | 121.11M |
| November 03, 2026 | 108.79M |
| November 02, 2026 | 106.69M |
| October 30, 2026 | 111.19M |
| October 29, 2026 | 119.00M |
| October 28, 2026 | 117.20M |
| October 27, 2026 | 110.29M |
| October 26, 2026 | 104.89M |
| October 23, 2026 | 101.88M |
| October 22, 2026 | 108.79M |
| October 21, 2026 | 109.09M |
| October 20, 2026 | 108.34M |
| October 19, 2026 | 98.88M |
| October 16, 2026 | 104.59M |
| October 15, 2026 | 113.90M |
| October 14, 2026 | 106.69M |
| October 13, 2026 | 113.60M |
| October 12, 2026 | 126.21M |
| October 09, 2026 | 128.17M |
| October 08, 2026 | 121.11M |
| October 07, 2026 | 116.90M |
| October 06, 2026 | 119.00M |
| October 05, 2026 | 130.72M |
| October 02, 2026 | 137.33M |
| Date | Value |
|---|---|
| October 01, 2026 | 133.12M |
| September 30, 2026 | 132.82M |
| September 29, 2026 | 133.72M |
| September 28, 2026 | 132.82M |
| September 25, 2026 | 138.83M |
| September 24, 2026 | 145.14M |
| September 23, 2026 | 152.65M |
| September 22, 2026 | 158.95M |
| September 21, 2026 | 154.75M |
| September 18, 2026 | 157.45M |
| September 17, 2026 | 152.35M |
| September 16, 2026 | 153.85M |
| September 15, 2026 | 153.25M |
| September 14, 2026 | 157.75M |
| September 11, 2026 | 162.26M |
| September 10, 2026 | 169.47M |
| September 09, 2026 | 177.28M |
| September 08, 2026 | 185.09M |
| September 04, 2026 | 194.70M |
| September 03, 2026 | 190.19M |
| September 02, 2026 | 188.99M |
| September 01, 2026 | 195.60M |
| August 31, 2026 | 195.00M |
| August 28, 2026 | 204.61M |
| August 27, 2026 | 215.73M |
Enterprise Value Definition
EV is considered the theoretical purchase ("takeover") price of a business because a purchaser would take on the company's debt, while pocketing the company's cash and gaining a right to all of the company's future earnings.
Enterprise Value Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Enterprise Value Benchmarks
| Arrowhead Pharmaceuticals, Inc. | 7.884B |
| Oncolytics Biotech, Inc. | 52.27M |
| Sangamo Therapeutics, Inc. | 38.97M |
| Sarepta Therapeutics, Inc. | 2.113B |
| Anixa Biosciences, Inc. | 89.83M |
Enterprise Value Related Metrics
| Net Income (Quarterly) | 13.72M |
| Total Expenses (Quarterly) | -13.72M |
| EPS Diluted (Quarterly) | 0.4595 |
| Earnings Yield | -84.85% |
| Normalized Earnings Yield | -57.95 |